Newron Pharmaceuticals SPA/ IT0004147952 /
| 2024-06-24 3:30:02 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 12.0000USD | - | 100 Turnover: 1,200 |
-Bid Size: - | -Ask Size: - | 161.11 mill.USD | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -0.91 EUR | -7.14% |
| EPS Diluted: | - EUR | -7.14% |
| Revenues per Share: | 0.51 EUR | 48.62% |
| Book Value per Share: | -1.68 EUR | 113.17% |
| Cash Flow per Share: | -0.57 EUR | -8.58% |
| Dividend per Share: | - EUR | - |
| Total | in mill. | |
| Revenues: | 9.06 EUR | 48.62% |
| Net Income: | -16.22 EUR | -7.25% |
| Operating Cash Flow: | -10.14 EUR | - |
| Cash and Cash Equivalents: | 6.34 EUR | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 16.42 | 11.03 |
| P/BV ratio: | -4.97 | -3.34 |
| P/CF Ratio: | -14.66 | -9.86 |
| PEG: | 1.28 | - |
| Earnings Yield: | -10.92% | -16.25% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 161.11 mill. USD | 110.43 mill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 17.85 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | -128.40% |
| Net Profit Margin: | -179.13% |
| Return on Equity: | - |
| Return on Assets: | -62.72% |
Financial Strength
| Liquidity I / Cash Ratio: | 21.91% |
| Liquidity II / Quick Ratio: | 46.29% |
| Liquidity III / Current Ratio: | 67.94% |
| Debt / Equity Ratio: | - |
| Dynam. Debt / Equity Ratio: | -550.04% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - EUR |
| Revenues / Employee: | - EUR |
| Net Income / Employee: | - EUR |
| Total Assets / Employee: | - EUR |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | EUR |
